Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Procter & Gamble's COX-2 inhibitor in preclinical testing

Dec. 24, 1997

Hyal discontinues development of osteoarthritis drug

Dec. 18, 1997

Pennsaid submitted to FDA for approval

Dec. 16, 1997

Selective COX-2 inhibitors under development at Merck Frosst

Dec. 16, 1997

Diphosphonate antiarthritic agent developed at Toray

Dec. 12, 1997

Antiinflammatory and COX-2-inhibitory effects reported for rutaecarpine

Dec. 8, 1997

Preclinical results reported for JTE-522, a selective COX-2 inhibitor

Dec. 5, 1997

FR-173657 effective in models of kinin-dependent inflammation

Dec. 5, 1997

Active principle of herbal medicine with immunomodulating effects

Dec. 4, 1997

Plant-derived biflavonoid with antiinflammatory activity

Dec. 4, 1997

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...